24/7 Market News Snapshot 02 June, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

June 2, 2025

DENVER, Colo., 02 June, 2025 (www.247marketnews.com) – (NASDAQ:IMNN) are discussed in this article.
Imunon, Inc. (IMNN) is witnessing a remarkable surge in market activity, with shares rising significantly from an opening price of $2.49 to a high of $3.06, reflecting an impressive increase of nearly 23%. This upward movement underscores a notable shift in investor sentiment, evident by a trading volume of 4.90 million shares. The prior day’s closing price positioned IMNN to capitalize on heightened interest from the market, prompting speculations regarding further potential advancements.

Contributing to this bullish trend is the announcement of substantial results from the company’s Phase 2 OVATION 2 Study, which will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and published in the peer-reviewed journal Gynecologic Oncology. This study centers on the therapeutic candidate IMNN-001, which has shown significant progress in frontline treatment strategies for advanced ovarian cancer. Key findings indicate that IMNN-001, when administered alongside standard neoadjuvant and adjuvant chemotherapy, has led to a median overall survival (OS) increase of 13 months compared to conventional treatments.

Particularly noteworthy is the enhanced efficacy observed in patients treated with poly ADP-ribose polymerase (PARP) inhibitors, with the median OS in the IMNN-001 cohort still unmatched, compared to 37 months in control groups. The study also highlighted promising outcomes for patients harboring BRCA mutations, reinforcing IMNN-001’s potential as a frontrunner in targeted therapies.

Imunon’s innovative TheraPlas platform strengthens IMNN-001’s application, suggesting possibilities beyond ovarian cancer and highlighting a commitment to maintaining a favorable safety profile without severe adverse events typical of other therapeutic options. Building on these encouraging results, Imunon is advancing its Phase 3 OVATION 3 Study, aimed at validating these transformative findings, with strong backing from the industry and a strategic financial outlook to revolutionize cancer care and improve patient outcomes.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.